Maraviroc: pharmacokinetics and drug interactions.
Article Details
- CitationCopy to clipboard
Abel S, Back DJ, Vourvahis M
Maraviroc: pharmacokinetics and drug interactions.
Antivir Ther. 2009;14(5):607-18.
- PubMed ID
- 19704163 [ View in PubMed]
- Abstract
Maraviroc is a potent selective CCR5 antagonist and is the first of this new class of oral agents to be approved for the treatment of CCR5-tropic HIV type-1. Maraviroc is extensively metabolized by CYP3A4, with renal clearance accounting for approximately 23% of total clearance. The half-life of maraviroc is approximately 16 h. Maraviroc does not inhibit any of the major CYP450 enzymes at clinically relevant doses and it has not shown any clinically relevant effects on plasma concentrations of other agents; hence, no dose adjustments of coadministered agents are required. Maraviroc exposure is altered by agents that modulate the activity of CYP3A4 and, in some circumstances, maraviroc dose adjustment is necessary. This article aims to review all pharmacokinetic and drug interaction data available for maraviroc, and to provide a comprehensive summary of the dose adjustment recommendations for maraviroc when coadministered with agents from all classes of antiretroviral therapy as well as other commonly coadministered agents.
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Maraviroc Cytochrome P450 3A4 Protein Humans UnknownSubstrateDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareMaravirocRitonavir The metabolism of Maraviroc can be decreased when combined with Ritonavir. MaravirocBoceprevir The metabolism of Maraviroc can be decreased when combined with Boceprevir. MaravirocVoriconazole The metabolism of Maraviroc can be decreased when combined with Voriconazole. MaravirocDitiocarb The metabolism of Maraviroc can be decreased when combined with Ditiocarb. MaravirocStiripentol The metabolism of Maraviroc can be decreased when combined with Stiripentol.